Insulin degludec 100 U/mL for treatment of spontaneous diabetes mellitus in dogs.

Insulin degludec 100 U/mL offers stable glycemic control in dogs with diabetes mellitus.

This prospective, multi-institutional, uncontrolled study evaluated the use of insulin degludec 100 U/mL (IDeg100) in 33 client-owned dogs with diabetes mellitus (DM). The study aimed to assess the level of diabetic control and identify any adverse effects associated with IDeg100 administration. The final median dose of IDeg100 was 1.3 U/kg, achieved over a median period of 14 days. Notably, 79% of the dogs had comorbidities, with 42% having more than one comorbidity. Additionally, 64% of the dogs were receiving concurrent medications, with 62% of these dogs on more than one non-insulin medication. The study found that IDeg100 provided consistent release and a predictable glucose-lowering effect, with minimal day-to-day variability. However, the study did not report any adverse effects associated with IDeg100 administration. The authors concluded that IDeg100 is a viable option for managing DM in dogs, offering stable glycemic control even in those with comorbidities and concurrent medications. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39844001/?utm_source=openai))

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.